Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **cadherin–catenin complex** is not a single molecule or canonical therapeutic target but rather a multi-protein assembly essential for calcium-dependent cell–cell adhesion in multicellular organisms[1][3][6]. The core components are **cadherins**, which are type-I transmembrane glycoproteins that mediate homophilic binding between cells through their extracellular domains. This adhesive function strictly requires the presence of extracellular calcium ions, which rigidify the cadherin structure and enable stable dimerization across adjacent cells[2][4][5]. On the cytoplasmic side, cadherins bind to **catenins**—notably β-catenin and α-catenin—which link the cadherins to the actin cytoskeleton. This linkage stabilizes adherens junctions and allows for mechanical signal transduction within tissues[3][4]. The entire assembly is often referred to as the "cadherin–catenin complex" or "adherens junction," playing critical roles in tissue morphogenesis, maintenance of epithelial layers, and regulation of cellular signaling pathways. Disruption or loss of this complex—particularly E-cadherin—is strongly associated with increased tumor invasiveness and metastasis in cancers such as carcinomas[1][3]. While no drugs directly target this structural protein assembly therapeutically, E-cadherin levels can serve as biomarkers for disease progression. The term "calcium-cadherin complex" is not standard; it likely refers imprecisely to either individual cadherins bound by calcium ions or more accurately to the broader multiproteic adherens junction/cadherin–catenin complexes. Thus, it is not considered a canonical drug target like receptors or enzymes but rather an essential structural component whose dysfunction has pathological consequences[1][6]. In summary: The so-called “calcium-cadherin complex” describes a multi-protein cell adhesion system dependent on calcium ions for its adhesive properties. It consists primarily of classical cadherins linked via catenins to actinic filaments at adherens junctions. It plays vital roles in tissue integrity and development; its disruption contributes significantly to cancer progression but it is not itself a direct therapeutic target nor does it have interacting drugs identified at present.[1][2][3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cadherin–catenin complex.